DIACARTA EU LIMITED

Diacarta EU Limited is a precision‑diagnostic company that delivers a one‑stop‑shop of molecular tests for the full cancer‑patient journey – from early‑stage screening and diagnosis through therapy selection and treatment monitoring. Leveraging its proprietary XNA and isobDNA™ technologies, Diacarta provides highly sensitive, cost‑effective detection of genetic alterations across a range of platforms, enabling clinicians to identify rare mutations in tissue biopsies and liquid‑biopsy samples with unmatched specificity.

The company’s portfolio includes the RadTox™ cfDNA assay for real‑time tumour‑response monitoring, the ColoScape™ test for colorectal‑cancer screening, and the Oncuria® bladder‑cancer assay, alongside a suite of infectious‑disease tests such as HPV and MonkeyPox diagnostics. All products are supported by ISO 13485‑certified GMP manufacturing, a CAP‑accredited CLIA laboratory and an innovative R&D hub, ensuring clinical excellence for healthcare providers and patients worldwide.

Headquartered in California with subsidiaries across Europe and Asia, Diacarta EU Limited combines world‑class scientific expertise with a patient‑centred approach, helping clinicians deliver personalised, evidence‑based care.